Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone

Haematologica

Volumn 94, Issue 12, 2009, Pages 1777-1778

  Telfer, Paul T ^a   Warburton, Fiona ^b   Christou, Soteroula ^c   Hadjigavriel, Michael ^d   Sitarou, Maria ^c   Kolnagou, Anita ^e   Angastiniotis, Michael ^f  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CITY UNIVERSITY   (United Kingdom)

^c Archbishop Makarios III Hospital   (Cyprus)

^d LIMASSOL GENERAL HOSPITAL   (Cyprus)

^e Paphos General Hospital   (Cyprus)

^f Thalassaemia International Federation   (Cyprus)

Author keywords

Chelation; Combination; Deferiprone; Desferrioxamine; Survival; Thalassaemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON;

ADULT; AGRANULOCYTOSIS; ALLERGY; ARTHRALGIA; BLOOD TRANSFUSION; CHELATION THERAPY; CYPRUS; DEATH; DRUG EFFICACY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EUROPEAN UNION; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEART LEFT VENTRICLE FUNCTION; HUMAN; INCIDENCE; IRON OVERLOAD; IRON STORAGE; LETTER; LIFE EXPECTANCY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NEUTROPENIA; OBSERVATION; PATIENT COMPLIANCE; SIDE EFFECT; SURVIVAL; THALASSEMIA MAJOR; TREATMENT DURATION; UNITED KINGDOM; WEIGHT GAIN;

ADULT; BETA-THALASSEMIA; CHELATION THERAPY; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IRON; IRON CHELATING AGENTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PYRIDONES; SIDEROPHORES; SURVIVAL ANALYSIS; TIME FACTORS; YOUNG ADULT;

EID: 73149099158     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.009118     Document Type: Letter

References (10)

1. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000;355:2051-2.
2. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89:1187-93.
3. Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica 2006;91:1187-92.
4. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008;10:42.
5. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998;103:361-4.
6. Aydinok Y, Ulger Z, Nart D, Terzi A, Cetiner N, Ellis G, et al. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica 2007;92:1599-606.
7. Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessi C, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005; 90:1309-14.
8. Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol 2006; 85:315-9.
9. Kattamis A, Ladis V, Berdousi H, Kelekis NL, Alexopoulou E, Papasotiriou I, et al. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cells Mol Dis 2006; 36:21-5.
10. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006; 107:3733-7.